文献速递消化内镜消化道肿瘤与早癌

一种创新的两步注射系统下一代内镜黏膜下注射材料(附视频)

An innovative next-generation endoscopic submucosal injection material with a 2-step injection system (with video).
PubMed 文献 · Gastrointest Endosc · 2020-06-18

研究开发由2.0%氯化钙溶液与0.4%海藻酸钠溶液组成的双溶液型下一代黏膜下注射材料,在离体猪胃/结肠模型上比较其与0.4%透明质酸钠溶液及海藻酸钠溶液的性能。结果显示下一代注射材料的黏膜下抬举高度更高、内镜黏膜下剥离术时间更短、总注射量更少。

要点

  • 下一代注射材料由2.0%氯化钙溶液与0.4%海藻酸钠溶液组成,利用钙离子使海藻酸钠黏弹性剧增。
  • 相同注射压力下,下一代注射材料的黏膜下抬举高度显著高于透明质酸钠或海藻酸钠。
  • 离体模型中下一代注射材料的内镜黏膜下剥离术时间与总注射量均低于透明质酸钠和海藻酸钠。

核心结论

  • 在离体模型中开发出兼具高性能与高灵活性的理想下一代黏膜下注射材料,作者认为需在患者人群中进一步研究。

研究设计与样本

  • 离体实验研究:测量透明质酸钠、海藻酸钠及下一代注射材料的黏弹性、黏膜下抬举高度和注射压力,并在离体猪胃/结肠模型的模拟病变上比较内镜黏膜下剥离术结果。

主要发现

  • 加入氯化钙后海藻酸钠黏弹性剧增,形成可由内镜医师控制的高黏度黏膜下垫。
  • 相同注射压力下,下一代注射材料的黏膜下抬举高度显著高于透明质酸钠或海藻酸钠。
  • 使用下一代注射材料的内镜黏膜下剥离术时间为14.2±6.1分钟,短于透明质酸钠的29.2±9.1分钟(P=.0004)和海藻酸钠的29.1±5.9分钟(P<.0001)。
  • 下一代注射材料的总注射量为7.0±0.9 mL,低于透明质酸钠的17.2±3.4 mL(P<.0001)和海藻酸钠的16.2±2.9 mL(P<.0001)。

关键数值与推荐

  • 下一代注射材料由2.0%氯化钙溶液和0.4%海藻酸钠溶液组成,采用两步注射系统。
  • 对照材料为0.4%透明质酸钠溶液和海藻酸钠溶液。

临床怎么用

  • 原文结论为在离体模型中开发出理想的下一代黏膜下注射材料,作者认为需在患者人群中进一步研究。

局限性

  • 研究仅在离体猪胃/结肠模型中进行。
  • 作者指出需在患者人群中进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Next-generation submucosal injection materials (SIMs) with higher performance and flexibility than the current SIMs (eg, 0.4% sodium hyaluronate solution [HA]) are expected to improve the outcomes of endoscopic submucosal dissection (ESD) but are difficult to develop. We developed a next-generation SIM by devising a 2-solution-type SIM comprising 2.0% calcium chloride solution (Ca) and 0.4% sodium alginate solution (SA) and evaluated its performance. METHODS: Viscoelasticity, submucosal elevation height, and injection pressure of HA, SA, and the next-generation SIM were measured. Outcomes of ESDs on pseudo-lesions in ex vivo porcine stomach/colon models were compared. RESULTS: The dramatic increase in SA viscoelasticity with the addition of Ca facilitated the formation of highly viscous submucosal cushions that can be controlled by endoscopists. The submucosal elevation height of the next-generation SIM was significantly higher than that of HA or SA with the same injection pressure. The ESD procedure time using the next-generation SIM was significantly shorter than that using HA or SA (14.2 ± 6.1 vs 29.2 ± 9.1 minutes, P = .0004, or 14.2 ± 6.1 vs 29.1 ± 5.9 minutes, P <.0001). Furthermore, the total injection volume for the next-generation SIM was considerably lower than that for HA or SA (7.0 ± 0.9 vs 17.2 ± 3.4 mL, P <.0001, or 7.0 ± 0.9 vs 16.2 ± 2.9 mL, P <.0001). CONCLUSIONS: We developed an ideal next-generation SIM that achieved high performance and high flexibility in ex vivo models. Our findings warrant further investigations in a patient population.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Hirose R, Nakaya T, Naito Y, et al. An innovative next-generation endoscopic submucosal injection material with a 2-step injection system (with video). Gastrointest Endosc. 2020. PMID: 32565186. doi:10.1016/j.gie.2020.06.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。